Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
XYLOCAINE is a combination injectable anesthetic containing lidocaine hydrochloride and epinephrine bitartrate, used for local and regional anesthesia. Lidocaine blocks nerve impulses by inhibiting sodium influx, while epinephrine causes vasoconstriction to prolong anesthetic effect and reduce systemic absorption. It is a foundational local anesthetic used across surgical, dental, and procedural settings.
As a mature, foundational anesthetic approaching loss of exclusivity with moderate competitive pressure, the brand team is likely focused on differentiation and operational efficiency rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Characterize the Phenotype in Patients With Morton's Neuroma and to Explore the Effect of Local Administration of Xylocaine (Lidocaine)
Working on XYLOCAINE offers limited dynamic growth but provides deep expertise in a foundational therapeutic category with decades of clinical evidence. This role is best suited for professionals interested in market defense, operational excellence, and sustained profitability in a mature segment rather than innovation-driven launches.
Worked on XYLOCAINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo